Apply CRISPR-Cas9 gene editing to high-throughput screening

(See a list of the products featured in this article.)

The CRISPR-Cas9 gene editing system provides an efficient approach for specific, complete, and permanent knockout of gene expression, making it a potent research tool for determining key players in specific biological pathways. The new Invitrogen™ LentiArray™ CRISPR libraries extend CRISPR-Cas9 technology into high-throughput applications for functional genomic screening. LentiArray libraries enable the interrogation of hundreds or thousands of genes in a single experiment with:

  • Advanced guide RNA (gRNA) designs for maximum knockout efficiency without sacrificing specificity
  • Up to 4 high-quality gRNAs per gene target, for efficient knockout in a wide variety of cell types
  • Two choices for delivery—high-titer, ready-to- use lentivirus, or glycerol stocks of E. coli containing lentiviral plasmids
  • A complete set of controls and lentiviruses against single-gene targets to support pre-screen assay development and rapid post-screen hit validation
  • 19 defined libraries and custom options available, enabling screens of defined gene sets or unbiased surveys of the whole genome (Table 1)

LentiArray library specifics

For example, the LentiArray Human Whole Genome CRISPR Library targets 18,453 genes with up to 4 gRNAs per gene target (pooled in a single well), for a total of 73,812 gRNAs. The gene targets within this library were selected using the most up-to-date genome databases, including the NCBI RefSeq database, and cross-referenced to the Gene Ontology Consortium (GO) database or the HUGO Gene Nomenclature Committee (HGNC). LentiArray CRISPR libraries are constructed using our proprietary CRISPR gRNA design algorithm, which incorporates the latest gRNA design research; gRNAs are selected for maximal editing efficiency and specificity and are designed to knock out all known isoforms of the target gene. Libraries are delivered as 100 μL of ready-to-use lentiviral particles per gene target at a titer of 1 x 108 TU/mL (functional titer determined by antibiotic resistance) and are also available as glycerol stocks (Table 1).

Table 1. Available defined libraries, supporting focused high-throughput screens as well as unbiased whole genome surveys.

ProductNo. of genesCat. No.
(ready to use)
Cat. No.
(glycerol stocks)
LentiArray Human Whole Genome CRISPR Library18,453Inquire A32185
LentiArray Human Druggable Genome CRISPR Library10,128Inquire A32184
LentiArray Human Apoptosis CRISPR Library904A42275A32176
LentiArray Human Cancer Biology CRISPR Library510A42268A32169
LentiArray Human Cell Cycle CRISPR Library1,444A42271A32172
LentiArray Human Cell Surface CRISPR Library778A42278A32179
LentiArray Human DNA Damage Response CRISPR Library561A42281A32182
LentiArray Human Drug Transport CRISPR Library98A42276A32177
LentiArray Human Epigenetics CRISPR Library396A42269A32170
LentiArray Human GPCR CRISPR Library446A42282A32183
LentiArray Human Ion Channel CRISPR Library328A42277A32178
LentiArray Human Kinase CRISPR Library840A42234A32167
LentiArray Human Membrane Trafficking CRISPR Library141A42272A32173
LentiArray Human Nuclear Hormone Receptor CRISPR Library47A42274A32175
LentiArray Human Phosphatase CRISPR Library288A42267A32168
LentiArray Human Protease CRISPR Library475A42279A32180
LentiArray Human Transcription Factor CRISPR Library1,817A42273A32174
LentiArray Human Tumor Suppressor CRISPR Library716A42280A32181
LentiArray Human Ubiquitin CRISPR Library943A42270A32171

Learn more about the LentiArray libraries

LentiArray CRISPR libraries are delivered in an arrayed format compatible with existing high-throughput screening infrastructure and have been designed and constructed to provide a flexible system that doesn’t impose limitations on your assay design. They utilize a two-vector design, expressing the Cas9 nuclease and the gRNA from separate lentiviral constructs, enabling you to dictate when and how the genome editing tools are delivered to your cells. Explore the LentiArray CRISPR libraries and find out how CRISPR-Cas9 technology can expand your screening capabilities.

Article download

Download a hyperlink-enabled, printer-friendly version of this article.
Download now